Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.

Abstract

CONTEXT:

Somatostatin (SST) and dopamine (DA) inhibit growth hormone (GH) secretion and proliferation of GH-secreting pituitary adenomas (GHomas) through binding to SSTR2 and D2R receptors. Chimeric SST-DA compounds (Dopastatins) display increased potency in inhibiting GH secretion, as compared with individual SST or DA analogs (alone or combined).

OBJECTIVE:

To assess the efficacy of a second-generation dopastatin, TBR-065, in suppressing GH secretion from human GH- and GH/prolactin(PRL)-omas.

DESIGN:

We compared the ability of TBR-065 to inhibit GH secretion from primary cultures of human GH- or GH/PRLoma cells to that of the first generation dopastatin, TBR-760 (formerly BIM-23A760), octreotide (OCT) and cabergoline (CAB), the later either alone or combined. We investigated whether there was any impact of BIM-133, the metabolite of TBR-065, on the ability of TBR-065 to inhibit GH in these cultures.

METHODS:

17 GH- and GH/PRLomas were included in this study. Inhibition of GH secretion by TBR-065, TBR-760, OCT and CAB (0.1 pM to 0.1 µM) was assessed over a period of 8 h.

RESULTS:

All tumors expressed SSTR2 and D2R mRNAs. GH suppression was higher with TBR-065 as compared with TBR-760 (Emax = 57 ± 5.6% vs. 41.1 ± 12.5%, respectively, p < 0.001) or with OCT + CAB (Emax = 56.8 ± 7.2% vs. 44.4 ± 9.4%, p < 0.001). BIM-133 did not have any impact on the activity of TBR-065.

CONCLUSION:

TBR-065 has significantly improved efficacy in suppressing GH secretion as compared to current available therapies and may represent a new promising option for the treatment of acromegaly.

• Authors: Thomas Cuny, Thomas Graillon, Célines Defilles, Rakesh Datta, Shengwen Zhang, Dominique Figarella-Branger, Henry Dufour, Grégory Mougel, Thierry Brue, Tanya Landsman, Heather A Halem, Michael D Culler, Anne Barlier, Alexandru Saveanu
• Journal: Pituitary (Pituitary) Vol. 24 Issue 3 Pg. 351-358 (Jun 2021) ISSN: 1573-7403 [Electronic] United States
• PMID: 33433890 (Publication Type: Journal Article)

Chemical References

• Receptors, Dopamine D2
• Receptors, Somatostatin
• Human Growth Hormone
• Somatostatin
• Cabergoline
• Octreotide
• Dopamine

Topics

• Adenoma (drug therapy)
• Cabergoline
• Dopamine
• Human Growth Hormone
• Humans
• Octreotide (pharmacology)
• Pituitary Neoplasms (drug therapy)
• Receptors, Dopamine D2
• Receptors, Somatostatin (genetics)
• Somatostatin (pharmacology)
• Tumor Cells, Cultured